Does "Congressman Fuji" ring a bell? Thatâs the moniker FDA scientists gave to ex-Rep. Christopher Shays (R-CT), who called the agency to express concern about the status of a breast-imaging device made by Connecticut-based Fujifilm Medical Systems, according to internal FDA documents provided to the New York Times. After that phone call, an FDA official ignored agency scientists and approved the device, the documents allege. FDA scientists wrote a letter to President-elect Obama last week alleging a pattern of "corruption" in the FDA division that reviews and approves medical devices. A spokeswoman for that division told ProPublica, "Weâre working directly with the transition team and weâll address their issues directly."
According to the AP, Hillary Clinton acted in the interest of her husbandâs donors at least six times. In one instance, she wrote to the FCC about a rate change she feared would hurt telecoms, citing a New York-based company whose chief executive later donated to her husbandâs foundation.
Thank you for your interest in republishing this story. You are are free to republish it so long as you do the following:
You have to credit ProPublica and any co-reporting partners. In the byline, we prefer “Author Name, Publication(s).” At the top of the text of your story, include a line that reads: “This story was originally published by ProPublica.” You must link the word “ProPublica” to the original URL of the story.
If you’re republishing online, you must link to the URL of this story on propublica.org, include all of the links from our story, including our newsletter sign up language and link, and use our PixelPing tag.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week,” and “Portland, Ore.” to “Portland” or “here.”)
You cannot republish our photographs or illustrations without specific permission. Please contact [email protected].
It’s okay to put our stories on pages with ads, but not ads specifically sold against our stories. You can’t state or imply that donations to your organization support ProPublica’s work.
You can’t sell our material separately or syndicate it. This includes publishing or syndicating our work on platforms or apps such as Apple News, Google News, etc.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually. (To inquire about syndication or licensing opportunities, contact [email protected].)
You can’t use our work to populate a website designed to improve rankings on search engines or solely to gain revenue from network-based advertisements.
We do not generally permit translation of our stories into another language.
Any website our stories appear on must include a prominent and effective way to contact you.
If you share republished stories on social media, we’d appreciate being tagged in your posts. We have official accounts for ProPublica on Twitter, Facebook and Instagram.
Copy and paste the following into your page to republish: